APA (7th ed.) Citation

Laniece Delaunay, C., Verdasca, N., Monge, S., Domegan, L., Sève, N., Buda, S., . . . Túri, G. (2025). COVID‐19 Vaccine Effectiveness Against Medically Attended Symptomatic SARS‐CoV‐2 Infection Among Target Groups in Europe, October 2024–January 2025, VEBIS Primary Care Network. Influenza & Other Respiratory Viruses, 19(5), 1. https://doi.org/10.1111/irv.70120

Chicago Style (17th ed.) Citation

Laniece Delaunay, Charlotte, et al. "COVID‐19 Vaccine Effectiveness Against Medically Attended Symptomatic SARS‐CoV‐2 Infection Among Target Groups in Europe, October 2024–January 2025, VEBIS Primary Care Network." Influenza & Other Respiratory Viruses 19, no. 5 (2025): 1. https://doi.org/10.1111/irv.70120.

MLA (9th ed.) Citation

Laniece Delaunay, Charlotte, et al. "COVID‐19 Vaccine Effectiveness Against Medically Attended Symptomatic SARS‐CoV‐2 Infection Among Target Groups in Europe, October 2024–January 2025, VEBIS Primary Care Network." Influenza & Other Respiratory Viruses, vol. 19, no. 5, 2025, p. 1, https://doi.org/10.1111/irv.70120.